11 completed, 7 unknown, 5 recruiting, 2 terminated. 8 Phase 4, 6 Not applicable, 6 Phase 2, 3 Phase 3, 2 Phase 1.
Follow Staphylococcus Aureus Bacteremia: new trials by email Literature Review of Staphylococcus Aureus Bacteremia trials Research Report on Staphylococcus Aureus Bacteremia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) - Staphylococcus Aureus Bacteremia | Phase 4 | Recruiting | Intermountain Health Care, Inc. | 2096 | 2026-02-01 | 2026-09-25 |
| Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia Dabigatran, Apixaban, edoxaban - Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia | Phase 4 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 300 | 2026-01-15 | 2026-09-24 |
| Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA - Staphylococcus Aureus Bacteremia | Phase 4 | Enrolling by invitation | West Virginia University | 300 | 2025-09-15 | 2026-09-17 |
| Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia Daptomycin for Injection, Vancomycin (IV) - Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia | Phase 4 | Recruiting | Todd C. Lee MD MPH FIDSA | 300 | 2024-11-14 | 2026-09-09 |
| Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia Staphylococcus Aureus Bacteremia | Active not recruiting | Hospital Universitari de Bellvitge | 369 | 2024-11-01 | 2024-11-22 | |
| Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid, IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline - Staphylococcus Aureus Bacteremia | Phase 3 | Unknown | Clinical Research Centre, Malaysia | 290 | 2024-06-28 | 2024-07-05 |
| Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia Ertapenem, Placebo - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia | Phase 2 | Recruiting | Todd C. Lee MD MPH FIDSA | 60 | 2024-05-20 | 2026-11-02 |
| Staphylococcus Aureus Bacteraemia (SAB)-Support-Study Checklist-based phone calls - Staphylococcus Aureus Bacteremia | Not applicable | Completed | University Medicine Greifswald | 124 | 2024-01-22 | 2025-11-21 |
| Evaluating Simplified Layered Consent for Clinical Trials Simplified layered consent form, Full-length consent form - Staphylococcus Aureus Bacteremia | Not applicable | Completed | Sunnybrook Health Sciences Centre | 347 | 2023-11-28 | 2026-10-19 |
| Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study). Echocardiography evaluation - Staphylococcus Aureus Bacteremia, Infective Endocarditis | Not applicable | Unknown | Puerta de Hierro University Hospital | 470 | 2023-09-04 | 2023-11-21 |
| 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia PET/CT - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia | Not applicable | Unknown | University College, London | 820 | 2023-09-01 | 2023-05-15 |
| Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association With Mortality and Development of Complicated Bacteremia Staphylococcus Aureus Bacteremia | Unknown | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 1000 | 2023-05-01 | 2024-08-27 | |
| Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia AP-SA02, Placebo - Bacteremia, Staphylococcus Aureus | Phase 1 / Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 56 | 2022-04-26 | 2026-03-23 |
| Staphylococcus Aureus Network Adaptive Platform Trial Cefazolin, Penicillin, Clindamycin - Staphylococcus Aureus Bacteremia | Phase 4 | Recruiting | University of Melbourne | 8000 | 2022-02-16 | 2026-05-06 |
| Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase Exebacase, Placebo - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 3 | Terminated | ContraFect | 259 | 2019-12-20 | 2023-11-02 |
| Oritavancin for Staphylococcus Aureus Infections in Opioid Users Oritavancin Injection - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 4 | Withdrawn | University of Pennsylvania | 2019-07-01 | 2022-04-06 | |
| Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia Ceftobiprole medocaril, Daptomycin - Staphylococcus Aureus Bacteremia | Phase 3 | Completed | Basilea Pharmaceutica | 390 | 2018-08-26 | 2026-10-07 |
| Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia Antibiotic therapy duration for 7 days - Staphylococcus Aureus Bacteremia | Phase 4 | Unknown | Thomas Benfield | 284 | 2018-06-01 | 2020-10-19 |
| Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia CF-301, Placebo - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 2 | Completed | ContraFect | 121 | 2017-05-23 | 2021-10-08 |
| Phase IIa Clinical Study of N-Rephasin® SAL200 N-Rephasin® SAL200, Placebo - Staphylococcus Aureus Bacteremia, Anti-Bacterial Agents | Phase 2 | Terminated | Intron Biotechnology, Inc. | 25 | 2017-03-07 | 2021-10-06 |
Showing 20 of 28. Sign in to see all of them.
Staphylococcal Infections (13) · Bacteremia (12) · Sepsis (4) · Arthritis, Rheumatoid (1) · Endocarditis (1) · Infections (1) · Recurrence (1)
Bacterial Infections (14) · Bacterial Infections and Mycoses (14) · Gram-Positive Bacterial Infections (13) · Infections (13) · Inflammation (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Systemic Inflammatory Response Syndrome (13) · Sepsis (9) · Arthritis (1) · Autoimmune Diseases (1) · Cardiovascular Diseases (1) · Connective Tissue Diseases (1) · Disease Attributes (1) · Heart Diseases (1)
Daptomycin (4) · Vancomycin (4) · Cefazolin (3) · Ceftaroline (3) · Clindamycin (2) · Ertapenem (2) · exebacase (2) · Adrenal Cortex Hormones (1) · Antirheumatic Agents (1) · Biological Products (1) · Cloxacillin (1) · Dabigatran (1) · Health Services (1) · Injections (1) · Lincomycin (1)
ContraFect (2) · Todd C. Lee MD MPH FIDSA (2) · Armata Pharmaceuticals, Inc. (1) · Basilea Pharmaceutica (1) · Bristol-Myers Squibb (1) · Clinical Research Centre, Malaysia (1) · Forest Laboratories (1) · Fundación Pública Andaluza Progreso y Salud (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Hospital Universitari de Bellvitge (1) · Intermountain Health Care, Inc. (1) · Intron Biotechnology, Inc. (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · National University Hospital, Singapore (1) · Puerta de Hierro University Hospital (1)
United States (10) · Spain (7) · Canada (6) · Germany (5) · Australia (4) · Israel (4) · United Kingdom (3) · Bulgaria (2) · France (2) · Greece (2) · Italy (2) · New Zealand (2) · Russia (2) · Singapore (2) · South Africa (2)
Todd C Lee, MD MPH FIDSA (2) · Achim J Kaasch, MD (1) · Anna Goodman (1) · Arif R Sawari, MD, MSc, MBA (1) · Brandon J Webb, MD (1) · Deborah Birx, MD (1) · Emily G McDonald, MD MSC (1) · Emily G McDonald, MD MSc (1) · Hong-Bin Kim, M.D, PhD (1) · Joy J Juskowich, MD (1) · Marc Engelhardt, MD (1) · Mark Rupp, M.D. (1) · Matthew P Cheng, MD (1)
PMID 41433510, PMID 22491776, PMID 23929889, PMID 27242721, PMID 2875256, PMID 31481566, PMID 32271718, PMID 33910968, PMID 37754204, PMID 38238170, PMID 38297916, PMID 39934879, PMID 40670317, PMID 41387009, PMID 42308484, PMID 42309115, PMID 6939390
2025 (2), 2017 (1)